BG Medicine, Inc. (BG Medicine) is a life sciences company focused on the discovery, development and commercialization of cardiovascular diagnostics to addresses unmet medical needs. The Company focuses on blood-based tests. Its lead product candidate in development is CardioSCORE, which is a multi-analyte biomarker-based blood test for atherothrombotic cardiovascular disease, commonly known as vulnerable plaque. In March 2011, the Company entered into a supply agreement with Health Diagnostic Laboratory, Inc. (HDL), pursuant to which HDL agreed to purchase manual galectin-3 test kits from the Company and to offer galectin-3 testing services to physicians in the United States. This manual version of Its Galectin-3 test is being marketed in the United States through a number of regional and national laboratory testing facilities. In addition, it has partnered with four diagnostic instrument manufacturers, which are developing automated instrument versions of its galectin-3 test.